FBIN filed a definitive proxy statement on March 30, 2026, providing shareholders with necessary information to vote on corporate matters at the upcoming annual meeting.

FBIN filed its 10-K on February 23, 2026, which includes sections on business operations, risk factors, and management's discussion and analysis. The provided excerpts do not contain specific financial metrics or detailed risk disclosures.

Fortress Biotech, Inc. filed an 8-K on February 12, 2026, likely reporting its fourth quarter and full-year financial results.

As of September 27, 2025, FBIN had $2.2 billion in aggregate outstanding unsecured senior notes and recently repaid its 4.000% senior notes using a combination of cash and commercial paper. The company maintains that it has the ability to obtain alternative financing if required. Key risks include the unpredictable timing and financial impact of potential acquisitions, share repurchases, or dividend payments.

Fortress Biotech, Inc. filed an 8-K on October 30, 2025, likely to report its third-quarter financial results.

As of June 28, 2025, FBIN held $2.2 billion in aggregate outstanding notes and recently repaid $500 million in 4.000% senior unsecured notes using cash and commercial paper. Key risks include the unpredictable timing and financial impact of potential acquisitions, joint ventures, share repurchases, or dividend payments on the company's operations and cash flows.